Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Kalvista Pharmaceuticals Inc (KALV)

Kalvista Pharmaceuticals Inc (KALV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 450,990
  • Shares Outstanding, K 42,188
  • Annual Sales, $ 0 K
  • Annual Income, $ -126,640 K
  • 60-Month Beta 0.89
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.69
Trade KALV with:

Options Overview Details

View History
  • Implied Volatility 55.47% ( -5.82%)
  • Historical Volatility 55.23%
  • IV Percentile 10%
  • IV Rank 13.05%
  • IV High 285.82% on 02/01/24
  • IV Low 20.90% on 07/12/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 32
  • Volume Avg (30-Day) 406
  • Put/Call OI Ratio 0.89
  • Today's Open Interest 11,779
  • Open Int (30-Day) 8,408

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 10/31/24
See More
  • Average Estimate -0.95
  • Number of Estimates 4
  • High Estimate -0.91
  • Low Estimate -1.03
  • Prior Year -0.80
  • Growth Rate Est. (year over year) -18.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.40 +6.44%
on 09/13/24
13.52 -18.14%
on 09/03/24
-1.17 (-9.56%)
since 08/19/24
3-Month
10.40 +6.44%
on 09/13/24
15.50 -28.58%
on 07/24/24
-0.30 (-2.64%)
since 06/18/24
52-Week
7.21 +53.54%
on 11/13/23
16.88 -34.42%
on 02/01/24
+1.15 (+11.59%)
since 09/19/23

Most Recent Stories

More News
Jobs Report Highlighted During Holiday-Shortened Week

Monday U.S. Economic Lookahead S&P final U.S. manufacturing PMI (June) Construction ...

DDD : 2.60 (+0.39%)
DZSI : 0.5500 (-5.17%)
PXD : 269.62 (+0.73%)
MSM : 85.89 (+4.81%)
SLP : 32.24 (+2.51%)
RDUS : 18.03 (+5.19%)
STZ : 248.67 (-0.93%)
KALV : 11.01 (+2.99%)
U.S. Inflation News Due out Next Week

Monday U.S. Featured Earnings Oracle Corporation (NYSE:ORCL) (Q1) Reported EPS of 90 cents ...

FLOW.TO : 0.1800 (unch)
GRA.TO : 2.32 (-3.54%)
CXI.TO : 24.75 (+2.48%)
ORCL : 167.02 (+1.51%)
CASY : 365.02 (-2.14%)
INNV : 6.00 (+0.17%)
EPM : 5.69 (+1.43%)
TSP : 0.2500 (-5.66%)
CBRL : 40.81 (-1.80%)
REVG : 28.07 (-1.16%)
IBEX : 19.83 (+0.51%)
ADBE : 526.44 (+3.60%)
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced...

KALV : 11.01 (+2.99%)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate...

KALV : 11.01 (+2.99%)
KalVista Pharmaceuticals to Present Data at the 13th C1-inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced...

KALV : 11.01 (+2.99%)
KalVista Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced...

KALV : 11.01 (+2.99%)
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results

KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided...

KALV : 11.01 (+2.99%)
KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented...

KALV : 11.01 (+2.99%)
KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced...

KALV : 11.01 (+2.99%)
KalVista Pharmaceuticals Provides Progress Updates on Sebetralstat Development

KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided...

KALV : 11.01 (+2.99%)

Business Summary

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which...

See More

Key Turning Points

3rd Resistance Point 11.38
2nd Resistance Point 11.18
1st Resistance Point 10.94
Last Price 11.01
1st Support Level 10.50
2nd Support Level 10.30
3rd Support Level 10.06

See More

52-Week High 16.88
Fibonacci 61.8% 13.19
Fibonacci 50% 12.05
Last Price 11.01
Fibonacci 38.2% 10.90
52-Week Low 7.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar